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There is accumulating evidence that up to 30%
of all late-life dementia is attributable to potentially
modifiable risk factors [1]. This has led to an increas-
ing attention for interventions targeting the mostly
vascular risk factors. The promise of potential pre-
vention has led to a series of randomized controlled
trials (RCTs) using single- or multidomain interven-
tions to slow down or prevent cognitive decline and
dementia. As opposed to the considerable number
of industry-sponsored RCTs using molecular tar-
gets, interventions targeting multiple vascular and
lifestyle-related risk factors generally aim to develop
widely implementable interventions for a broad pop-
ulation at increased risk of dementia.
The existing data suggest modest impact from
interventions for individuals, but so limited are
the good news stories in dementia research that
such findings have been seized on with enthusiasm.
The FINGER trial from Finland, targeting multiple
dementia risk factors in persons with no cognitive
impairment, shows a small excess improvement in
cognition over the considerable improvement seen in
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the control group after 24 months [2]. This glimpse
of hope has been taken up with funding for FINGER
style studies across the globe, with local adaptation.
Other large trials, including preDIVA and MAPT, did
not show a significant effect on their respective pri-
mary endpoints all-cause dementia after 72 months
and cognitive decline after 36 months [3, 4]. Both
studies have pointed toward areas of improvement
and potential subgroups in whom this type of inter-
ventions may be more effective.
In this edition there are three papers on new
investigator-initiated prevention trials. These include
two protocols on multi-domain interventions and one
providing much needed evidence about adherence
to a single-domain intervention on physical activ-
ity. It should be noted that none of these provide
results from a phase III RCT. This raises the question
whether the previous phase III trials, which were gen-
erally neutral, were simply performed too soon with
insufficient development of combinations of effec-
tive interventions, and the current studies prepare the
ground for large scale phase III trials with a higher
chance of success. For the two study protocols and
the results of the phase II trial reported here, we
focus on their approaches to the question they seek
to address. Different target populations, intervention
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types, and outcome measures used, betray the strug-
gle of the field to find the optimal strategy to reach
the common goal: prevention (or postponement) of
cognitive decline and dementia. A crucial question
is what the future value of these studies will be for
wider populations in real-world settings.
A remarkable difference between the three pre-
sented studies is the choice of the target population.
All select persons at increased risk of dementia,
based on the presence of individual risk factors. But
while the SMARRT trial targets persons between 70
and 89, the AIBL and MYB studies target much
younger populations of over 60 and 55–77, respec-
tively [5–7]. This illustrates the previously discussed
trade-off between the optimal window of interven-
tion versus the optimal window for effectiveness
assessment [8].
Studies on dementia prevention use a wide range
of outcomes, ranging from a biomarker such as hip-
pocampal volume on MRI, to all-cause dementia. All
three studies in this issue use cognitive decline as an
effectiveness outcome measure. MYB is powered to
detect a 0.1 standard deviation difference on a cog-
nitive test battery, which raises the question whether
such an effect should be considered proof of concept,
or proven efficacy. All-cause dementia is generally
the preferred outcome, since its clinical relevance is
beyond doubt. But this outcome may not always be
feasible because of the length of follow up and fund-
ing required. Although often used, cognition as an
outcome poses problems of interpretation and mean-
ing in its relevance to lived lives. The treatment effect
in the FINGER trial is a good example: a statistically
significant difference on a standardized composite
cognitive score between the intervention and con-
trol group was found, but the effect size was small,
and both intervention and control groups improved.
This renders the meaning for long-term cognitive
functioning uncertain. This is a challenging ques-
tion for agencies such as the FDA and EMA; does
a small effect on an intermediate outcome like cogni-
tive decline justify large-scale, and expensive in terms
of opportunity cost given limited resources, imple-
mentation? And how large should such an effect be,
and how sustainable should it be before we accept
it as proof of effectiveness? Although the SMARRT
pilot trial will use change in cognitive functioning for
the sample size calculation for the full-scale trial, it
will potentially be able to power for all-cause demen-
tia due to the target age range of 70–89, depending on
the expected effect size and planned study duration
of the full trial.
The decision to proceed to implementation of an
intervention with a small effect may depend on the
type of intervention. Low-risk interventions, such as
lifestyle interventions, can be taken to the implemen-
tation phase (including assessment of cost, capacity,
and resource implications) after showing a relatively
small effect, even on an intermediate outcome such
as a cognitive test. Such studies should also incor-
porate evaluation of long-term effectiveness related
to clinical outcomes and risk of adverse events. If
effectiveness for clinical outcomes remains uncer-
tain, such implementation should be reviewed. This is
rarely the case currently when ‘good ideas’ are rushed
into policy without such care and attention. In con-
trast to such low-risk approaches, intensive diagnostic
processes and high risk or expensive interventions,
such as immunotherapy, must be tested not only for
efficacy but also effectiveness and harm for clinically
relevant outcomes with clear benefit beyond doubt
before investment in robust implementation with pop-
ulations of relevance.
Adherence to prevention programs is notoriously
difficult to sustain. Results from the AIBL study are
encouraging, showing that motivated people in the
setting of an RCT resulting from a cohort study can
sustainably adhere to a physical activity intervention.
The finding is in line with previous reports on adher-
ence from the multidomain FINGER trial, which used
a similar approach by recruiting from a pool of partic-
ipants in longitudinal observational studies. However,
such populations of volunteers are highly atypical of
those at increased risk of future dementia. Any find-
ings must therefore be confirmed in a less structured
real-world setting. The recruitment in SMARRT is
closer to a real-world setting, recruiting from an inte-
grated health care system in the US, although these
are not fully population representative. Before imple-
mentation in a true real-world setting, an acceptable
level of sustained adherence in relevant populations
should be made tested and deliverable.
The three studies use different modes of delivery
of the intervention. The intervention in SMARRT is
rather intensive, aiming for at least a monthly face
to face meeting with a healthcare worker. This may
not be implementable in large parts of the world
due to both logistical and financial reasons. The
MYB, on the other hand, will use an approach which
is completely online. This offers many advantages,
and will be much easier and cheaper to implement.
However, previous studies have shown that blended
approaches, i.e., combining an online intervention
with human support, are probably more effective
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[9]. In this light, the results of the HATICE trial,
probing a multi-domain interactive coach-supported
internet intervention to improve the cardiovascular
risk profile, are eagerly awaited [10]. The planned
PRODEMOS RCT will take this one step further
and will use a smartphone-based approach to reduce
the risk of dementia, aiming to make dementia pre-
vention available across the globe including settings
with generally less access to preventive health care
[11]. An important consideration to probe an online
strategy, particularly using a smartphone, is that
there may be little room for improvement left in
high income countries, whereas in many low- and
middle income countries (LMIC), economic growth
and increasing prosperity are accompanied by an
increase in unhealthy lifestyles. Smartphone posses-
sion is steeply on the rise in LMIC, making preventive
approaches within reach for millions of people who
previously hardly had access to health care.
Finally, the recently published SPRINT-MIND
has been interpreted as showing encouraging results
suggesting that intensive blood pressure lowering
may prevent cognitive decline and dementia [12].
Although the study failed to show a statistically sig-
nificant effect on all-cause dementia, it has been
argued it was underpowered because of early termi-
nation due to substantial beneficial effect on incident
cardiovascular disease. Dementia risk reduction stud-
ies will need to be carefully integrated with initiatives
that cardiovascular disease taking into account this
and other learning such as population evidence on the
‘side effects’ that might be usual in real world popu-
lations, but appear to be much lower in the SPRINT
study creating concern about the implementation of
guidance into frailer populations.
With so many prevention studies completed and
ongoing, it is time to take stock. The Interna-
tional Research Network on Dementia Prevention
(IRNDP) is a promising initiative in an emerg-
ing area bringing the global research community
together, including LMICs in which risk is probably
rising. The European Dementia Prevention Initia-
tive (EDPI; http://www.edpi.org) has shown that
collaboration can be instrumental, with three large
international dementia prevention studies coming
forth from such collaboration (HATICE, MIND-AD,
and PRODEMOS). IRNDP may be a global platform
for discussions on future trial design, such as the ques-
tion whether we should take a step back and consider
interventions targeting the population, rather than the
individual. The AIBL proof of concept for sustainable
adherence, the carefully designed pilot study neces-
sary for a proper sample size calculation in SMARRT,
and the ambitious MYB study may all inspire future
dementia prevention study designs.
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